World /

COVID-19: Lilly antibody treatment trial paused over safety concern

Pharma giant pauses late-stage trial of experimental lab-produced antibody treatment

Last updated: October 14, 2020 | 02:41

AFP

1 MIN READ

Shutterstock

Also In This Package

Half of Chinese city of 9m swabbed for COVID in 2 days

Dead, ill, recovered: Celebrities hit by COVID-19

Cafe hits sweet spot with virus-shaped dessert

Trump resumes campaign after bout with COVID-19

Washington: US pharmaceutical firm Eli Lilly on Tuesday paused a late-stage trial of its experimental lab-produced antibody treatment against COVID-19 over an unspecified safety concern, the company said.

“Lilly is supportive of the decision by the independent DSMB (data safety monitoring board) to cautiously ensure the safety of the patients participating in this study,” a spokesperson said in a statement.

Get the latest news and updates straight to your inbox